I-SPY 2 redefines breast cancer subtypes to better match patients to treatment
Using multi-omic data from nearly 1,000 patients across 10 trial arms, I-SPY 2 researchers developed a new response-predictive subtyping framework incorporating immune, DNA repair, luminal, and HER2 phenotypes — now being tested in I-SPY 2.2. The dataset has been made publicly available.
Featured by Inside Precision Medicine, this research highlights a major advancement from the I-SPY 2 trial in redefining breast cancer subtypes to improve precision treatment. By analyzing multi-omic data from nearly 1,000 patients across 10 clinical trial arms, researchers developed a new response-predictive framework that goes beyond traditional classifications. The new model integrates key biological features—including immune activity, DNA repair mechanisms, luminal characteristics, and HER2 phenotypes—to better predict how individual patients are likely to respond to specific therapies. This more comprehensive approach enables clinicians to make more informed treatment decisions and supports the development of truly personalized cancer care. The framework is now being evaluated in the I-SPY 2.2 trial, where researchers continue to refine patient selection and accelerate the identification of effective therapies. To encourage collaboration and future discoveries, the complete dataset has also been made publicly available, providing valuable resources for researchers worldwide. This work represents another important milestone in precision oncology, demonstrating how advanced molecular profiling can improve clinical trial design, enhance treatment matching, and ultimately lead to better outcomes for patients with breast cancer.